What was the primary outcome of Novo Nordisk's late-stage study of its oral GLP-1 drug in youth with type 2 diabetes?

Novo Nordisk's oral GLP-1 drug met the primary goal of a late-stage study in children and adolescents aged 10 to 17 years with type 2 diabetes, as announced by the company on Thursday.

In which patient population did Novo Nordisk's oral GLP-1 drug demonstrate success in its late-stage trial?

The drug demonstrated success in a late-stage trial involving children and adolescents aged 10 to 17 years with type 2 diabetes.

Novo Nordisk's Oral GLP-1 Drug Meets Primary Goal in Late-Stage Diabetes Study

Apr 23, 2026

Novo Nordisk announced its oral GLP-1 drug successfully met the primary endpoint in a late-stage study involving children and adolescents aged 10 to 17 with type 2 diabetes.

reuters

2026-02-25

Novo Nordisk Taps Start-Up for New Oral Weight-Loss Drugs

2026-04-13

Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development

2026-04-23

Novo Nordisk's Oral GLP-1 Drug Meets Primary Goal in Late-Stage Diabetes Study

2026-05-05

Novo Nordisk's first-quarter profit beats forecasts

2026-05-26

Global Firms Bring More Work In-House at India Hubs on AI Boost